Trevi Therapeutics heads into its third-quarter report with an odd disconnect. Last quarter management sounded more confident than at any point in the past year. It had launched two major cough trials, raised $162 million, extended its cash runway into 2030 and watched a rival exit the refractory chronic cough race. Yet the stock has fallen about 29% since then, while the S&P 500 slipped only modestly. The report, due after the close on November 9, will not settle any efficacy question. It can show whether the execution story management described is still on schedule as the company approaches its first meaningful interim test.
The numbers themselves are unlikely to move the needle much. Analysts expect a loss of 13 cents a share, wider than the 11-cent loss last quarter and well above the 8-cent loss a year ago. That works out to roughly a 62% deterioration year over year. For a pre-revenue company with more than 200 global trial sites coming online, a wider loss is evidence of activity, not trouble. The share count also expanded after the April offering, which makes per-share comparisons less clean. Of greater interest is the cash line. Trevi ended the second quarter with about $319 million. Investors should check whether the burn rate still supports the into-2030 runway that management has reaffirmed since early this year. Any trimming of that runway would carry more weight than a penny of EPS variance.
Operationally, the first test is OCEAN-2, the 12-week Phase III study in idiopathic pulmonary fibrosis cough. Management slated it to begin in the third quarter. Confirmation that it started on time, alongside steady enrollment in the 52-week OCEAN-1 trial and the Phase IIb LAKE study in refractory chronic cough, would support management's claim of strong investigator enthusiasm and no competing enrollment. Investors should also look for an update on the non-IPF interstitial lung disease program. Trevi had requested an FDA meeting and expected a decision on it shortly after the last call. A clear regulatory path there would add a third leg to the story. Silence or ambiguity would leave it as a footnote.
The bigger catalyst sits just beyond this report. LAKE's sample size re-estimation is expected in the fourth quarter. That timing makes any color on enrollment pace and the expected interim schedule especially valuable now. Management has said the review could enlarge the trial by up to 50% if conditional power falls short. It describes that outcome as a statistical adjustment rather than an efficacy signal. The market may not be so charitable, given that a competitor's refractory chronic cough failure highlighted how placebo response can undo Phase 2 promise. Reaffirmed timing would keep the narrative intact. Any slippage would feed the skepticism already visible in the shares.
That skepticism is notable. Sentiment has swung to 83.2% bearish from 44.8% heading into the last report. At $13.63, the stock sits below its 200-day moving average of $14.34 and in the lower half of its post-earnings range of $11.70 to $19.30. It has also slipped beneath last quarter's $13.12 to $20.22 band at times. The bar is low, but so is the patience. There is also a known overhang. The current runway does not fund the 24-week OCEAN-1 primary readout in the first half of 2028, the refractory chronic cough Phase III or a launch, so another raise is effectively assumed.
The central question is whether Trevi can show that its shift into full execution mode is running on time and on budget. If OCEAN-2 is under way, the LAKE interim remains on track for year-end and the runway holds, the improving narrative from last quarter survives intact despite the stock's slide. If timelines slip or cash burn outpaces plan, the bears will have their evidence well before any efficacy data arrive.